BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fattizzo B, Kulasekararaj AG. Second-Generation C5 Inhibitors for Paroxysmal Nocturnal Hemoglobinuria. BioDrugs 2020;34:149-58. [PMID: 31916226 DOI: 10.1007/s40259-019-00401-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Menon D, Urra Pincheira A, Bril V. Emerging drugs for the treatment of myasthenia gravis. Expert Opin Emerg Drugs 2021;26:259-70. [PMID: 34228579 DOI: 10.1080/14728214.2021.1952982] [Reference Citation Analysis]
2 Fattizzo B, Serpenti F, Giannotta JA, Barcellini W. Difficult Cases of Paroxysmal Nocturnal Hemoglobinuria: Diagnosis and Therapeutic Novelties. J Clin Med 2021;10:948. [PMID: 33804461 DOI: 10.3390/jcm10050948] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Hussein NH, Amin NS, El Tayebi HM. GPI-AP: Unraveling a New Class of Malignancy Mediators and Potential Immunotherapy Targets. Front Oncol 2020;10:537311. [PMID: 33344222 DOI: 10.3389/fonc.2020.537311] [Reference Citation Analysis]
4 Lee SE, Lee JW. Safety of current treatments for paroxysmal nocturnal hemoglobinuria. Expert Opin Drug Saf 2021;20:171-9. [PMID: 33249943 DOI: 10.1080/14740338.2021.1857723] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Cheng WY, Sarda SP, Mody-Patel N, Krishnan S, Yenikomshian M, Mahendran M, Lejeune D, Yu LH, Duh MS. Real-World Healthcare Resource Utilization (HRU) and Costs of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Eculizumab in a US Population. Adv Ther 2021;38:4461-79. [PMID: 34275086 DOI: 10.1007/s12325-021-01825-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]